DRD2 agonists have been shown to suppress PRL-induced adenomyosis and also have therapeutic potential for reducing pain and treating adenomyosis, likely through the promotion of the long isoform of PRLR (PRLR-L) and the inhibition of angiogenesis by DRD2 [140,141,142,143]. This evidence concerns the gene PRLR and adenomyosis.